Halozyme Therapeutics Reports Director and Officer Changes
Ticker: HALO · Form: 8-K · Filed: Mar 21, 2025 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | 8-K |
| Filed Date | Mar 21, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
Related Tickers: HALO
TL;DR
Halozyme's board and exec comp are changing, watch for new strategy.
AI Summary
On March 17, 2025, Halozyme Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a shift in leadership and potential adjustments to how key personnel are compensated.
Why It Matters
Changes in a company's board and executive compensation can signal strategic shifts or reflect responses to performance, potentially impacting investor confidence and future company direction.
Risk Assessment
Risk Level: medium — Changes in executive and director roles can introduce uncertainty about future strategy and leadership stability.
Key Players & Entities
- HALOZYME THERAPEUTICS, INC. (company) — Registrant
- March 17, 2025 (date) — Date of Earliest Event Reported
- 001-32335 (other) — Commission File Number
- Delaware (other) — State of Incorporation
- 12390 El Camino Real (other) — Principal Executive Offices Address
- San Diego (other) — City of Principal Executive Offices
- 92130 (other) — Zip Code of Principal Executive Offices
FAQ
What specific changes were made to the board of directors?
The filing indicates a reportable event concerning the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific details of these changes are not provided in the provided text.
What are the details of the new compensatory arrangements?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, but the specific terms and amounts of these arrangements are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 17, 2025.
What is Halozyme Therapeutics, Inc.'s Commission File Number?
Halozyme Therapeutics, Inc.'s Commission File Number is 001-32335.
In which state is Halozyme Therapeutics, Inc. incorporated?
Halozyme Therapeutics, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 21, 2025 regarding HALOZYME THERAPEUTICS, INC. (HALO).